- Home
- ALEC vs DMAC Comparison
ALEC vs DMAC Comparison
Compare ALEC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- DMAC
- Stock Information
- Founded
- ALEC 2013
- DMAC 2000
- Country
- ALEC United States
- DMAC United States
- Employees
- ALEC N/A
- DMAC N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ALEC Health Care
- DMAC Health Care
- Exchange
- ALEC Nasdaq
- DMAC Nasdaq
- Market Cap
- ALEC 232.6M
- DMAC 274.1M
- IPO Year
- ALEC 2019
- DMAC N/A
- Fundamental
- Price
- ALEC $1.86
- DMAC $4.82
- Analyst Decision
- ALEC Buy
- DMAC Strong Buy
- Analyst Count
- ALEC 6
- DMAC 3
- Target Price
- ALEC $11.75
- DMAC $7.00
- AVG Volume (30 Days)
- ALEC 2.3M
- DMAC 118.6K
- Earning Date
- ALEC 11-06-2024
- DMAC 11-13-2024
- Dividend Yield
- ALEC N/A
- DMAC N/A
- EPS Growth
- ALEC N/A
- DMAC N/A
- EPS
- ALEC N/A
- DMAC N/A
- Revenue
- ALEC $61,508,000.00
- DMAC N/A
- Revenue This Year
- ALEC N/A
- DMAC N/A
- Revenue Next Year
- ALEC $71.71
- DMAC N/A
- P/E Ratio
- ALEC N/A
- DMAC N/A
- Revenue Growth
- ALEC N/A
- DMAC N/A
- 52 Week Low
- ALEC $1.73
- DMAC $2.14
- 52 Week High
- ALEC $8.90
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- ALEC 22.54
- DMAC 47.28
- Support Level
- ALEC $1.74
- DMAC $5.05
- Resistance Level
- ALEC $2.50
- DMAC $5.74
- Average True Range (ATR)
- ALEC 0.16
- DMAC 0.37
- MACD
- ALEC 0.03
- DMAC -0.08
- Stochastic Oscillator
- ALEC 2.37
- DMAC 28.10
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.